Sulphasalazine in ankylosing spondylitis.

Abstract

In recent years sulphasalazine has gained acceptance as an effective agent for the treatment of rheumatoid arthritis. Ankylosing spondylitis is a disease where remission inducing drugs so far have been lacking. In this double blind trial sulphasalazine was compared with placebo in 37 patients with ankylosing spondylitis. Evaluation after three months' treatment showed reduction of inflammatory activity and improvement of clinical variables. The side effects were mild. The results suggest that sulphasalazine is a potentially effective and safe drug in the treatment of ankylosing spondylitis.

• Authors: N Feltelius, R Hällgren
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 45 Issue 5 Pg. 396-9 (May 1986) ISSN: 0003-4967 [Print] England
• PMID: 2872857 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Haptoglobins
• Orosomucoid
• Sulfasalazine

Topics

• Adult
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Haptoglobins (analysis)
• Humans
• Male
• Middle Aged
• Orosomucoid (analysis)
• Spondylitis, Ankylosing (blood, drug therapy)
• Sulfasalazine (therapeutic use)